• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Prucalopride     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatEthers, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAmidesyago:WikicatBenzofuransyago:WikicatMolecularFormulasyago:WikicatMotilityStimulantsyago:Abstraction100002137yago:Amide114724264yago:Benzofuran114898101yago:Chemical114806838yago:Cognition100023271yago:Communication100033020yago:Compound114818238yago:Element114840755yago:Formula106816935yago:Information105816287yago:LanguageUnit106284225yago:Material114580897yago:Matter100020827yago:Message106598915yago:MolecularFormula106817173yago:Name106333653yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:PsychologicalFeature100023100yago:Quintessence114847103yago:Relation100031921yago:WikicatJohnson&JohnsonBrandsdrugyago:Statement106722453yago:Stimulation105827684yago:Substance100019613yago:TradeName106845599yago:WikicatEthers New Facet based on Instances of this Class

Prucalopride, brand names Resolor and Motegrity among others, is a drug acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements. Prucalopride was approved for medical use in the European Union in 2009, in Canada in 2011, in Israel in 2014, and in the United States in December 2018. The drug has also been tested for the treatment of chronic intestinal pseudo-obstruction.